A treatment to reverse the symptoms of Alzheimer's is moving to human trials
An aging population means Alzheimer's is becoming increasingly common. Image: REUTERS/Nacho Doce
Get involved with our crowdsourced digital platform to deliver impact at scale
Stay up to date:
Neuroscience
Remember, Remember
A drug-free dementia reversal treatment is making the leap from animals to humans.
In 2015, researchers at the Queensland Brain Institute (QBI) in Australia published the results of a study in which they successfully reversed the symptoms of dementia, a type of mental decline that most often manifests as Alzheimer’s disease, in animal models — without using any drugs at all.
On Tuesday, Australia’s Federal Minister for Health announced plans to give those researchers $10 million in federal funding to begin safety testing their dementia reversal technique in humans.
Of Mice And Humans
The QBI team’s promising technique centers on the use of ultrasound technology.
When applied to the brain region, the waves of the ultrasound temporarily open up what’s called the blood-brain barrier. This activates mechanisms that break apart and clear the toxic amyloid plaques associated with dementia.
This technique has already effectively restored memory function in mice and sheep, and with the $10 million in funding, the QBI team will be able to begin safety testing it in humans in late 2019.
Next Steps
Safety testing is just the first step in moving a new therapy from the research lab to the consumer market. If it’s showed to be safe, the QBI team’s ultrasound treatment will then need to undergo Phase II and III trials to confirm its effectiveness. In other words, this is a huge step forward — but it’s just the first of several.
Still, if the QBI team is able to navigate the clinical trial process, the reward at the end of the journey will be well worth the effort.
“This funding will ensure we keep some of the world’s brightest minds focused on finding a cure for dementia,” researcher Jurgen Gotz told the Australian Broadcasting Corporation. “The goal, long-term, is to come up with an affordable, portable device, which would help the millions of Alzheimer’s patients in our country and worldwide.”
Don't miss any update on this topic
Create a free account and access your personalized content collection with our latest publications and analyses.
License and Republishing
World Economic Forum articles may be republished in accordance with the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Public License, and in accordance with our Terms of Use.
The views expressed in this article are those of the author alone and not the World Economic Forum.
The Agenda Weekly
A weekly update of the most important issues driving the global agenda
You can unsubscribe at any time using the link in our emails. For more details, review our privacy policy.
More on Health and Healthcare SystemsSee all
Shyam Bishen
October 10, 2024
Shyam Bishen
October 10, 2024
Manica Balasegaram
October 10, 2024
Dr George Cheriyan
October 8, 2024
Simon Torkington
October 8, 2024
Ewan Thomson and Madeleine North
October 7, 2024